Utemuradova G E
Zh Mikrobiol Epidemiol Immunobiol. 2009 May-Jun(3):98-100.
To study etiologic structure of acute enteric infections (AEI) with isolation of hemolytic and enteropathogenic Escherichia and to assess the efficacy of probiotic therapy during infections caused by E. coli.
Bacteriologic tests were performed in 245 children < 3 years old with acute enteric infection. Influence of Colibacterin and Bifidumbacterin preparations on the dynamics of infectious process was assessed.
Hemolytic Escherichia, enteropathogenic E. coli, Shigella spp., and Salmonella spp. were isolated in 47.3%, 12.2%, 18.3%, and 1.8% of patients with AEI, respectively. The cause of AEI was identified in 77.1% of cases. Bifidumbacterin had good therapeutic effect on infections caused by pathogenic E. coli including its hemolytic forms.
Treatment with Bifidumbacterin improved state of the patients and resulted in suppression of growth of hemolytic Escherichia in the gut. Colibacterin had a good therapeutic effect in the group of patients with domination of staphylococci, enterococci, Proteus in the gut as well as in patients with isolated Shigella and Salmonella. Colibacterin is contraindicated in cases of colonization of the intestine by hemolytic E. coli.
研究急性肠道感染（AEI）的病因结构，分离溶血性和肠道致病性大肠杆菌，并评估益生菌疗法对大肠杆菌引起的感染的疗效。
对245名3岁以下患有急性肠道感染的儿童进行细菌学检测。评估大肠杆菌菌苗和双歧杆菌制剂对感染过程动态的影响。
在AEI患者中，分别有47.3%、12.2%、18.3%和1.8%分离出溶血性大肠杆菌、肠道致病性大肠杆菌、志贺氏菌属和沙门氏菌属。77.1%的病例确定了AEI的病因。双歧杆菌制剂对致病性大肠杆菌（包括其溶血型）引起的感染有良好的治疗效果。
双歧杆菌制剂治疗改善了患者状况，并抑制了肠道中溶血性大肠杆菌的生长。大肠杆菌菌苗对肠道中以葡萄球菌、肠球菌、变形杆菌为主的患者组以及分离出志贺氏菌和沙门氏菌的患者有良好的治疗效果。溶血性大肠杆菌在肠道定植的情况下，大肠杆菌菌苗是禁忌的。
